P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Documenti analoghi

• C012 | NOVEL ANALYSIS OF RESULTS FROM THE PIVOTAL EPCORE NHL-1 STUDY: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND COMPLETE RESPONSE AT 2-YEARS WITH EPCORITAMAB MONOTHERAPY
  di: P.L. Zinzani, et al.
  Pubblicazione: (2025-09-01)
• Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma
  di: Lorenzo Falchi, et al.
  Pubblicazione: (2026-12-01)
• P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
  di: Wojciech Jurczak, et al.
  Pubblicazione: (2023-08-01)
• Metabolic pitfall of pseudoprogression after epcoritamab treatment
  di: Osamu Imataki, et al.
  Pubblicazione: (2024-12-01)
• Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience
  di: Chakrapani Balijepalli, et al.
  Pubblicazione: (2025-04-01)